221 related articles for article (PubMed ID: 30993395)
1. Long-term thiazide use and risk of low-energy fractures among persons with Alzheimer's disease-nested case-control study.
Taipale H; Rysä J; Hukkanen J; Koponen M; Tanskanen A; Tiihonen J; Kröger H; Hartikainen S; Tolppanen AM
Osteoporos Int; 2019 Jul; 30(7):1481-1489. PubMed ID: 30993395
[TBL] [Abstract][Full Text] [Related]
2. Incident hip fractures among community dwelling persons with Alzheimer's disease in a Finnish nationwide register-based cohort.
Tolppanen AM; Lavikainen P; Soininen H; Hartikainen S
PLoS One; 2013; 8(3):e59124. PubMed ID: 23527106
[TBL] [Abstract][Full Text] [Related]
3. Risk of Hip Fracture in Benzodiazepine Users With and Without Alzheimer Disease.
Saarelainen L; Tolppanen AM; Koponen M; Tanskanen A; Sund R; Tiihonen J; Hartikainen S; Taipale H
J Am Med Dir Assoc; 2017 Jan; 18(1):87.e15-87.e21. PubMed ID: 27847263
[TBL] [Abstract][Full Text] [Related]
4. Which is the preferred site for bone mineral density monitoring as an indicator of treatment-related anti-fracture effect in routine clinical practice? A registry-based cohort study.
Leslie WD; Martineau P; Bryanton M; Lix LM
Osteoporos Int; 2019 Jul; 30(7):1445-1453. PubMed ID: 31016351
[TBL] [Abstract][Full Text] [Related]
5. Proton pump inhibitor use and risk of hip fractures among community-dwelling persons with Alzheimer's disease-a nested case-control study.
Torvinen-Kiiskinen S; Tolppanen AM; Koponen M; Tanskanen A; Tiihonen J; Hartikainen S; Taipale H
Aliment Pharmacol Ther; 2018 Apr; 47(8):1135-1142. PubMed ID: 29508411
[TBL] [Abstract][Full Text] [Related]
6. Optimal age of commencing and discontinuing thiazide therapy to protect against fractures.
Kruse C; Eiken P; Vestergaard P
Osteoporos Int; 2016 May; 27(5):1875-85. PubMed ID: 26659068
[TBL] [Abstract][Full Text] [Related]
7. Incident Use of a Potentially Inappropriate Medication and Hip Fracture in Community-Dwelling Older Persons With Alzheimer's Disease.
Hyttinen V; Taipale H; Tolppanen AM; Tanskanen A; Tiihonen J; Hartikainen S; Valtonen H
Ann Pharmacother; 2017 Sep; 51(9):725-734. PubMed ID: 28486815
[TBL] [Abstract][Full Text] [Related]
8. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
McClung MR; O'Donoghue ML; Papapoulos SE; Bone H; Langdahl B; Saag KG; Reid IR; Kiel DP; Cavallari I; Bonaca MP; Wiviott SD; de Villiers T; Ling X; Lippuner K; Nakamura T; Reginster JY; Rodriguez-Portales JA; Roux C; Zanchetta J; Zerbini CAF; Park JG; Im K; Cange A; Grip LT; Heyden N; DaSilva C; Cohn D; Massaad R; Scott BB; Verbruggen N; Gurner D; Miller DL; Blair ML; Polis AB; Stoch SA; Santora A; Lombardi A; Leung AT; Kaufman KD; Sabatine MS;
Lancet Diabetes Endocrinol; 2019 Dec; 7(12):899-911. PubMed ID: 31676222
[TBL] [Abstract][Full Text] [Related]
9. Antidepressant use and risk of hip fractures among community-dwelling persons with and without Alzheimer's disease.
Torvinen-Kiiskinen S; Tolppanen AM; Koponen M; Tanskanen A; Tiihonen J; Hartikainen S; Taipale H
Int J Geriatr Psychiatry; 2017 Dec; 32(12):e107-e115. PubMed ID: 28055139
[TBL] [Abstract][Full Text] [Related]
10. Comparison of predictors of hip fracture and mortality after hip fracture in community-dwellers with and without Alzheimer's disease - exposure-matched cohort study.
Tolppanen AM; Taipale H; Tanskanen A; Tiihonen J; Hartikainen S
BMC Geriatr; 2016 Dec; 16(1):204. PubMed ID: 27908278
[TBL] [Abstract][Full Text] [Related]
11. Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States.
Burge RT; Disch DP; Gelwicks S; Zhang X; Krege JH
Osteoporos Int; 2017 Mar; 28(3):799-809. PubMed ID: 28028555
[TBL] [Abstract][Full Text] [Related]
12. Antipsychotic Use and the Risk of Hip Fracture Among Community-Dwelling Persons With Alzheimer's Disease.
Koponen M; Taipale H; Lavikainen P; Tanskanen A; Tiihonen J; Tolppanen AM; Ahonen R; Hartikainen S
J Clin Psychiatry; 2017 Mar; 78(3):e257-e263. PubMed ID: 28146612
[TBL] [Abstract][Full Text] [Related]
13. Drug use in persons with and without Alzheimer's disease aged 90 years or more.
Taipale H; Koponen M; Tanskanen A; Tolppanen AM; Tiihonen J; Hartikainen S
Age Ageing; 2016 Nov; 45(6):900-904. PubMed ID: 27609205
[TBL] [Abstract][Full Text] [Related]
14. Comparison of hip fracture and osteoporosis medication prescription rates across Canadian provinces.
Crilly RG; Kloseck M; Chesworth B; Mequanint S; Sadowski E; Gilliland J
Osteoporos Int; 2014 Jan; 25(1):205-10. PubMed ID: 23907572
[TBL] [Abstract][Full Text] [Related]
15. Incidence and Duration of Cumulative Bisphosphonate Use among Community-Dwelling Persons with or without Alzheimer's Disease.
Tiihonen M; Taipale H; Tanskanen A; Tiihonen J; Hartikainen S
J Alzheimers Dis; 2016; 52(1):127-32. PubMed ID: 26967224
[TBL] [Abstract][Full Text] [Related]
16. A comparison of case-finding strategies in the UK for the management of hip fractures.
Johansson H; Kanis JA; Oden A; Compston J; McCloskey E
Osteoporos Int; 2012 Mar; 23(3):907-15. PubMed ID: 22234810
[TBL] [Abstract][Full Text] [Related]
17. Thiazide diuretics and the risk of hip fracture after stroke: a population-based propensity-matched cohort study using Taiwan's National Health Insurance Research Database.
Lin SM; Yang SH; Cheng HY; Liang CC; Huang HK
BMJ Open; 2017 Sep; 7(9):e016992. PubMed ID: 28963293
[TBL] [Abstract][Full Text] [Related]
18. Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years.
Ferrari S; Adachi JD; Lippuner K; Zapalowski C; Miller PD; Reginster JY; Törring O; Kendler DL; Daizadeh NS; Wang A; O'Malley CD; Wagman RB; Libanati C; Lewiecki EM
Osteoporos Int; 2015 Dec; 26(12):2763-71. PubMed ID: 26068295
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Risk of Osteoporotic Fracture in Denosumab vs Alendronate Treatment Within 3 Years of Initiation.
Pedersen AB; Heide-Jørgensen U; Sørensen HT; Prieto-Alhambra D; Ehrenstein V
JAMA Netw Open; 2019 Apr; 2(4):e192416. PubMed ID: 31002319
[TBL] [Abstract][Full Text] [Related]
20. Acetylcholinesterase inhibitors and the risk of osteoporotic fractures: nested case-control study.
Tamimi I; Nicolau B; Eimar H; Arekunnath Madathil S; Kezouh A; Karp I; Tamimi F
Osteoporos Int; 2018 Apr; 29(4):849-857. PubMed ID: 29264626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
